Ocuphire Pharma to Present at Two Investor Conferences in August
Ocuphire Pharma (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company, has announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ocuphire Pharma (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company, has announced its participation in two upcoming investor conferences. Dr. George Magrath, the company's CEO, will present at:
1. The Canaccord Genuity 44th Annual Growth Conference in Boston, MA on August 14, 2024 at 9:00 a.m. ET in a fireside chat format.
2. The H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024 at 10:30 a.m. ET, delivering a presentation.
Ocuphire Pharma focuses on developing small-molecule therapies for retinal and refractive eye disorders. Company management will be available for one-on-one meetings during both conferences. Interested parties can contact their conference representative or email ir@ocuphire.com to arrange meetings.
Details
News Market Reaction – OCUP
The recorded move for OCUP in the trading session of this news was +6.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that George Magrath, M.D., M.B.A., M.S., Chief Executive Officer, will present at the Canaccord Genuity 44th Annual Growth Conference, to take place in Boston, MA, August 14, 2024, and at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, to take place virtually, on August 15, 2024.
| Event: | Canaccord Genuity 44th Annual Growth Conference |
| Location: | Boston, MA |
| Presenter: | Dr. George Magrath |
| Date: | August 14, 2024 |
| Time: | 9:00 a.m. ET |
| Format: | Fireside Chat |
| Event: | H.C. Wainwright 4th Annual Ophthalmology Virtual Conference |
| Location: | Virtual |
| Presenter: | Dr. George Magrath |
| Date: | August 15, 2024 |
| Time: | 10:30 a.m. ET |
| Format: | Presentation |
Company management will also be available for one-on-one meetings throughout the conferences. If you are interested in arranging a meeting, please contact your conference representative or send an email to ir@ocuphire.com.
About Ocuphire Pharma
Ocuphire Pharma, Inc. (Nasdaq: OCUP) is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of patients with retinal and refractive eye disorders. Ocuphire’s lead product candidate, APX3330, a novel small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein), is in development for diabetic retinopathy. In addition, Ocuphire’s late-stage product candidate Phentolamine Ophthalmic Solution
Contacts
| Corporate | Investor Relations |
| Nirav Jhaveri, M.B.A. CFO ir@ocuphire.com | Corey Davis, Ph.D. LifeSci Advisors cdavis@lifesciadvisors.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.